1	Pro	moting <u>S</u> moking <u>Ce</u> ssation and <u>P</u> reven <u>t</u> ing <u>Re</u> lapse to Tobacco Use following a smokefree		
2	mental health in-patient stay (SCEPTRE feasibility study): a multi-centre randomised controlled			
3		feasibility study protocol.		
4				
5	Petal Pe	etersen Williams* (1,2,3), Lisa Huddlestone (1), Emily Shoesmith (1), Samantha Brady (4), Alex		
6	Mitchell (4), Victoria Exley (4), Fraser Wiggins (4), Lesley Sinclair (4), Jodi Pervin (1), Michelle			
7	Horspool (5), Moira Leahy (5), Claire Paul (6), Lesley Colley (7), Lion Shahab (8), Jude Watson (4),			
8	Catherine Hewitt (4), Simon Hough (9), John Britton (10), Tim Coleman (11), Simon Gilbody (1, 12),			
9	Steve P	arrott (1), Paul Galdas (1), Gregor Russell (13), Peter Coventry (1,14), Elena Ratschen (1)		
10				
11 12	1.	Mental Health and Addiction Research Group, Department of Health Sciences, University of York, UK		
13 14	2.	Mental Health, Alcohol, Substance Use and Tobacco Research Unit, South African Medical Research Council. South Africa		
15 16	3.	Institute for Life Course Health Research, Department of Global Health, Stellenbosch University, South Africa		
17	4.	York Trials Unit, University of York, UK		
18	5.	Research and Development, Sheffield Health and Social Care NHS Foundation Trust,		
19	6	Sheffield, UK Research and Development, Loods and York Partnership NHS Foundation Trust, Loods, UK		
20	0. 7	Research and Development, Leeus and Tork Partnership NHS Foundation Trust, Leeus, OK		
22	,.	Tees, UK		
23	8.	Department of Behavioural Science and Health, University College London, London, UK		
24	9.	Independent PPI Co-applicant, Cheshire, UK		
25	10.	University of Nottingham, UK Contro for Academic Primany Caro, University of Nottingham, Nottingham, UK		
20 27	11. 12	Hull York Medical School University of York York UK		
28	13.	Research and Development, Bradford District Care NHS Foundation Trust, Bradford, UK		
29	14.	York Environmental Sustainability Institute, University of York, York, UK		
30				
31				
32				
33				
34				
35				
36	*Corresp	ponding author: Petal Petersen Williams, PhD, Mental Health and Addiction Research Group, Department of Health		
37	Sciences,	University of York, Heslington, York Y010 5DD, UK. <i>E-mail address: <u>petal.petersenwilliams@york.ac.uk</u> Tel: +44</i>		
38	(0)1904 3	32 4923		
39				
40	Keywo	rds: Tobacco, smoking, mental illness, feasibility, smoking cessation, intervention		
41	Words:	4872		

#### 42 ABSTRACT

#### 43 Introduction

44 Thousands of patients with mental illness are admitted to acute adult mental health wards every 45 year in England, where local guidance recommends that all mental health settings be entirely 46 smokefree. Mental health trusts presently invest substantial effort and resources to implement 47 smokefree policies and to deliver tobacco dependence treatment to patients. Providing adequate 48 support can help smokers remain abstinent or quit smoking during their smokefree inpatient stay 49 and beyond. At present, little is known about how best to support patients to prevent their return to 50 pre-admission smoking behaviours after discharge from a smokefree mental health inpatient stay. 51 We have developed an intervention which includes targeted resources to support smoking-related 52 behaviour change in patients following discharge from a smoke-free mental health setting. The aim 53 of this trial is to determine the feasibility of a large-scale clinical trial to test the effectiveness and 54 cost-effectiveness of the SCEPTRE intervention, compared with usual care.

#### 55 Methods and Analysis

56 This feasibility study will be an individually randomised, controlled trial in eight National Health 57 Service (NHS) mental health trusts recruiting adults (≥18 years) admitted to an acute adult mental 58 health inpatient setting who are tobacco smokers on admission, or at any point during their inpatient 59 stay. Consenting participants will be randomised to receive a 12-week intervention consisting of 60 components aimed at promoting or maintaining positive smoking-related behaviour change 61 following discharge from a smoke-free mental health inpatient setting or usual care. Data will be 62 collected at baseline, 3-months and a second timepoint between 4-6 months post-randomisation. 63 With 64 participants (32 in each group) the trial will allow a participation rate of 15% and completion 64 rate of 80% to be estimated within a 95% confidence interval of ±3% and ±10% respectively. The 65 analysis will be descriptive and follow a prespecified plan.

#### 66 **Ethics and Dissemination**

Ethics approval was obtained from the North West - Greater Manchester West Research Ethics Committee. We will share results widely through local, national and international academic, clinical and Patient and Public Involvement (PPI) networks. The results will be disseminated through conference presentations, peer-reviewed journals and will be published on the trial website: https://sceptreresearch.com/.

72 Trial registration number: ISRCTN77855199

- 73
- 74
- . 1
- 75

76	Strengths and limitations of this study
77	
78	• The use of a theory and evidence-based intervention to support smoking cessation and
79	prevent relapse to tobacco following a smokefree mental health inpatient stay, can be
80	effective for impacting long term smoking behaviour.
81	• The objective of the SCEPTRE feasibility trial is to test recruitment and radomisation of
82	participants and collection of proposed outcome data in planning for a large randomised
83	controlled trial.
84	Quantitative and qualitative methods will be used to determine if research and intervention
85	processes are acceptable and feasible and inform the decision of progression to full trial.
86	• The outcomes to be assessed will be relevant to patients, carers, mental health professionals,
87	and policymakers.
88	• The present study is limited to English speaking adults admitted to acute mental health
89	inpatient wards.
90	Usual care varies greatly within and between Trusts nationally, making comparisons between
91	intervention and standard care heterogenous.
92	
93	
94	
95	
96	
97	
98	
99	
100	
101	
102	
103	
104	
105	
106	
107	
108	
109	

#### 110 INTRODUCTION

111 Tobacco smoking remains one of the leading preventable causes of death and disease in England and 112 is responsible for an estimated 74,600 deaths annually [1, 2]. Although smoking prevalence in the UK 113 has steadily declined over the last few decades, rates remain at least 50% higher for people with 114 mental health conditions compared to those without [3]. With average smoking prevalence figures of 115 40%, people with mental illness are more than twice as likely to smoke compared to those without 116 [4]. Even higher smoking rates of up to 70% are seen in subgroups, such as hospitalised patients with 117 mental health conditions [4, 5]. This results in substantially increased risks of premature smoking-118 related morbidity and mortality in this population [4]. Up to 20 life years are lost largely due to 119 diseases related to smoking and this is the biggest contributor to the health inequalities experienced 120 by people with mental illness [6].

121

Although people with mental health conditions are able [7] and more likely to be motivated [8] to quit smoking than those without, mainstream stop-smoking services are not commonly accessed by this population [9, 10] and are decreasingly resourced to support the needs of smokers with mental illness for tailored support [11-13]. However, National Institute for Health and Care Excellence (NICE) [14] guidance recommends that all mental health settings be entirely smokefree without exemption, with no facilitated smoking breaks, and evidence-based tobacco dependence treatment for smoking cessation, harm reduction and support for temporary abstinence available to all patients who smoke.

129

130 For many people with mental illness, a smokefree inpatient stay constitutes a rare or first experience 131 as an adult of sustained abstinence, near-abstinence, or substantial reduction of tobacco 132 consumption [15]. Evidence suggests individuals can successfully remain abstinent during their 133 smokefree inpatient stay when behavioural and/or pharmacological support is offered [15, 16]. 134 However, while a smokefree stay may result in temporary abstinence from tobacco or cessation, the 135 risk of relapse post-discharge is high [17] with many individuals returning to smoking within a few 136 days [18]. A lack of support in the immediate post-discharge period and the resulting relapse or 137 return to heavy prehospital smoking patterns renders efforts and resources during the inpatient 138 episode inefficient, as positive smoking behaviour change achieved during the inpatient stay may be 139 lost. Therefore, it is vital to provide support post-discharge to prevent relapse.

140

141 The overall aim of the Promoting Smoking Cessation and Preventing Relapse to Tobacco use 142 following a smokefree mental health in-patient stay (SCEPTRE) study is to determine the feasibility 143 and acceptability of delivering the multi-component SCEPTRE intervention in National Health Service

(NHS) adult mental health services. A second objective is to describe the initial effect of this intervention on participants' smoking-related outcomes. We will also carry out a process evaluation and obtain feedback from all stakeholders relating to the research participation process and the acceptability of the intervention and gain an understanding of the importance and potential impact of individual intervention components. Finally, we will estimate the cost of delivering the SCEPTRE intervention and the control condition and the feasibility of collecting health economic data.

150

#### 151 METHODS AND ANALYSIS

The SCEPTRE feasibility trial protocol is reported in accordance with the guidelines presented in the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist [19] and the Template Intervention Description and Replication guidelines [20]. See supplemental appendix 1 for SPIRIT checklist.

156

#### 157 Patient and public involvement (PPI)

158 The SCEPTRE PPI group is integral to the trial and consists of six current/recent smokers with lived 159 experience of a mental health inpatient stay and their carers. Members have contributed to the 160 design of the intervention components, participant study documents, intervention resources, and 161 intervention delivery mechanisms and measures. The group meets quarterly to provide feedback on 162 study progress and have been kept up to date with frequent trial updates. Additionally, the 163 Programme Steering Committee (PSC) has an independent lay member representative. The results of 164 the study will be made available to trial participants, PPI panel members, participating NHS trusts 165 and the wider public through the trial website and other popular media.

166

#### 167 Trial design

An individually randomised, controlled feasibility trial will be conducted with embedded qualitative interviews and health economic component (see Consolidated Standards of Reporting Trials (CONSORT) diagram in Fig. 1).

171

172 [insert figure 1]

173

#### 174 Study setting

Participants will be recruited from up to eight English NHS mental health Trusts. To be eligible to participate, trusts must be committed to, and working towards full implementation of smokefree policy in line with national guidance [14].

#### 178

## 179 Participants

180 To be eligible for inclusion in this study, participants must (1) be aged 18 years and older (no 181 maximum age); (2) be admitted to an acute adult mental health inpatient ward; (3) if detained under 182 the mental health act, be granted unescorted (Section 17) leave i.e. leave the ward without being 183 supervised (4) have discharge planned to an address/accommodation within the trust's catchment 184 area or a pre-defined radius agreed with participating trusts; (5) be a tobacco smoker at time of 185 admission or at any point after (as patients occasionally still commence smoking after admission) and 186 express an interest in maintaining abstinence if smokefree at time of assessment. Or express an 187 interest in positively changing their smoking behaviour following discharge (including reduction of 188 cigarette consumption; using e-cigarettes); (6) be able to understand and communicate in English; (7) 189 have access to a telephone or computer/alternative digital device to receive post-discharge support; 190 and (8) be willing and able to provide informed consent. Patients currently being treated within a 191 psychiatric intensive care unit (PICU) will not be recruited. Additionally, those deemed not suitable to 192 being approached to participate in the study (at clinician discretion) and those discharged to any 193 trust accommodation with a smokefree policy will be ineligible to participate.

194

#### **195 Participant recruitment and study procedures**

#### 196 Patient identification and screening for eligibility

Participating trusts will identify, from electronic patient records, all patients who have been recorded on or after admission as a current smoker. Trust-based researchers will also visit participating wards and work with ward staff and other healthcare professionals to identify potential participants meeting the inclusion criteria. Potentially eligible participants will be approached by a member of the Trust research team to ascertain their interest in the study and seek permission to provide further information about the research. Screened patients will be recorded, along with reasons for ineligibility, non-approach and non-consent, in the eligibility screening log.

204

Ward staff will be encouraged to actively promote the study, for example, during ward community meetings and interactions with patients (e.g., during pre-discharge assessments and discharge planning). Patients who are identified as potential participants but who are too unwell to participate will be frequently reviewed to allow participation in the study when their mental health allows.

209

#### 210 Informed consent and data collection

211 Consent will be obtained in-person or remotely via telephone/video call. All participants will have 212 received a copy of the PIS at least 24 hours prior to obtaining consent. The consent form will also 213 contain optional statements in relation to consent to interview for the qualitative aspect of the study. 214

215 Once participant eligibility has been confirmed and consent obtained, participants will be asked to 216 complete a baseline questionnaire. If required, consent procedures and collection of baseline data 217 can be separated into two visits dependent on participant preference. Data will be collected either 218 using bespoke case report forms (CRFs) completed electronically via the secure web-based outcome 219 data collection interface 'REDCap', over the telephone with a SCEPTRE researcher, or collected on 220 paper CRFs returned via free post envelopes to York Trials Unit (YTU). All reporting of data collection 221 will be undertaken in line with the CONSORT statement [22]. The baseline assessment includes socio-222 demographic information as well as information on mental and physical health and smoking history 223 and behaviour. Participants who self-report they have not smoked will be asked to provide an expired 224 air carbon monoxide (CO) reading. We will ask participants for full contact details at baseline 225 (including mobile phone number, email, and address), and any contact preferences.

226

227 After the baseline assessment is completed, a member of the trust's research team will randomise 228 participants to either the intervention or comparison group. All participants (intervention and 229 control) will be followed up for the purposes of the study via self-completed questionnaires at 3 230 months and 4-6 months post-randomisation to accommodate a variable second follow-up period 231 which allows us to extend the recruitment period without extending the duration of the study 232 overall. During the follow-up, outcome measures to be collected include smoking-related measures 233 and mental and physical health measures. While completing the follow-up questionnaires, 234 participants who self-report that they have not smoked in the previous seven days will be invited to 235 undertake a CO measurement to validate their abstinence from tobacco. Participants who decline 236 the invitation will be asked to provide a reason for declining, and this will be recorded on the 237 questionnaire.

238

At three months and the relevant follow up timepoints, a link to complete the relevant electronic questionnaire on REDCap will be sent to participants via email, with the option to send a paper copy to participants for postal completion or completion with a researcher over the phone or in person instead as preferred. If participants select self-completion without a researcher and report abstinence from tobacco use within the previous 7 days, then a researcher will contact the participant to arrange a suitable time to obtain a CO reading in person to validate self-report. If no

response is received within one week, an automated reminder will be sent to the participant. If participants do not respond following the automated reminder, a member of the research team will contact the participant via their preferred contact preference to prompt completion. Participants will receive shopping vouchers for completing the two follow-up assessments.

249

## 250 <u>Qualitative interviews</u>

251 Participants from both the control and intervention arms will be invited to take part in a short semi-252 structured interview following the completion of the SCEPTRE trial to gain a more in-depth 253 understanding of the acceptability and feasibility of the study procedures. Interviews, guided by a 254 schedule of topics developed from the APEASE criteria will examine the intervention delivery 255 process, facilitators, and barriers of delivering the intervention, as well as the obtaining feedback 256 from intervention arm participants. This will allow for future refinement and improvement of the 257 intervention and research processes involved. Between nine and 12 patient participants in total (6-8 258 participants from the intervention arm; 3-4 participants from the control arm) will be interviewed. 259 Up to four informal caregivers that can include family and friends (but not exclusively) of participants 260 in the intervention arm will be invited to participate in short semi-structured interviews at 3-month 261 follow-up to obtain their views on the acceptability and feasibility of intervention delivery methods. 262 Semi-structured interviews will also be conducted with the leading mental health worker delivering 263 the intervention from each of the Trusts in the week following the completion of the final participant 264 in the intervention. Interviews will explore their experience and perceptions of delivering the 265 intervention and assess the fidelity of delivery. Up to six trust stakeholders will be invited to 266 participate in online focus group discussions (FGDs) to explore the experiences and perceptions of 267 trust-based stakeholders of supporting the conduct of the research.

268

#### 269 Randomisation and blinding

270 Randomisation will be 1:1 to either the intervention or comparison arm, stratified by recruiting site 271 and using randomly permuted blocks of randomly varying sizes. The randomisation schedule will be 272 generated by a statistician at YTU not involved in the recruitment of participants and will be 273 implemented in the REDCap system to ensure allocation concealment. Following a baseline 274 assessment, randomisation will be undertaken by a member of the Trust's research team. Due to the 275 nature of the SCEPTRE intervention, the trust-based researchers and participants will not be blinded 276 to allocation. The trial statistician conducting the analyses will not be blinded. Following allocation to 277 a study arm, the researcher will receive an email with the participant's allocation attached. The 278 outcome of the allocation will be communicated to the participant where possible in person but may

also be communicated by text or telephone call. Those participants randomised to the intervention arm will be contacted by the interventionist to arrange a time to complete the pre-discharge assessment. Details of participants allocated to the control group will be provided to ward staff to allow for the delivery of the usual tobacco dependency support offered by the trust. All participants' GPs will be informed of their allocation by letter. A copy of the GP letter will also be held in the Trust electronic notes, so Community Mental Health Teams (CMHTs) are aware of patients' participation in the study.

286

#### 287 Intervention

#### 288 <u>Control arm: usual care</u>

Participants randomised to the control arm will receive usual care. The local offer of smoking cessation support is variable across NHS mental health trusts. Usual care in some trusts may be comprehensive and include behavioural and pharmacological support during admission, whereas others may provide limited support (e.g., access to nicotine replacement therapy). Detailed information on what usual care entails on each inpatient ward will be collected. All participants will be provided with information of how to access Stop Smoking Services post-discharge.

295

#### 296 Intervention arm: SCEPTRE intervention package

297 Participants assigned to the intervention group will receive a 12-week intervention consisting of 298 components aimed at promoting or maintaining smoking-related behaviour change among patients 299 following discharge from a smoke-free mental health inpatient setting. See Fig. 2 for the SCEPTRE 300 intervention pathway. The intervention development process was guided by the Behaviour Change 301 Wheel model [23] and theoretically underpinned by the Theoretical Domains Framework [24] and 302 the Behavioural Change Technique taxonomy [25]. Intervention components were identified and 303 further developed based on two systematic reviews and a Delphi-style consultation process with key 304 stakeholders, including clinicians and patients [16, 21, 26]. To ensure fit within the context of mental 305 health services, refinement of the draft intervention was undertaken in collaboration with clinicians 306 and experts in the field of tobacco control, and members of the SCEPTRE PPI panel. A more detailed 307 description of the intervention and its development is provided elsewhere [21]. The intervention will be delivered by trained mental health workers, named 'My-Try Specialists' (MTSs). The manualised 308 309 intervention consists of several core and additional components outlined in Table 1.

- 310
- 311
- 312

## 313

314

## Table 1. Summary of individual SCEPTRE intervention components

Intervention component	Core/ additional	Aim	Frequency	Delivery
Pre-discharge reflection, evaluation and goal setting sessions	Core	Provide personalised and tailored support to assist participants in identifying and planning their smoking-related behaviour change goals. Discussions will also determine if participants want to use additional intervention components.	Participant-led; may include up to two sessions lasting up to 45 minutes	MTS to deliver
Provision of a bespoke and personalised resource folder: My-Try kit	Core	Kit including practical information and motivational content to support participants following discharge.	One kit provided pre-discharge	MTS to provide kit
Nicotine Replacement Therapy (NRT)/e- cigarette selection and advice	Core	To discuss preferences for NRT or e-cigarette support as well as practical advice in relation to using the products and obtaining a longer-term supply.	Discussed during pre-discharge reflection and evaluation session, and MTS will continue to provide advice in behavioural support calls	MTS to deliver
Tailored behavioural support calls (via telephone or video call)	Core	Provide personalised and tailored support, assist the participant in maintaining positive change achieved during their smokefree admission and achieving their behaviour change goals, and provide feedback and encouragement on participant's progress.	Calls lasting 10-30 minutes for 12- weeks. On the first five days post-discharge, calls will be made daily, and weekly thereafter for the remaining eleven weeks	MTS to deliver
Smoke Free app	Additional	Provide additional support to participants, including its offer of 24/7 live smoking cessation advisor support	As required	MTS to deliver 'onboarding' session; smoking cessation advisors to provide advice via app
Text-based support	Additional	Personalised text messages to provide practical and motivational information to participants based on their	15-30 text messages for 8- 15 days dependent on	MTS to deliver

# individual goals (Appendix 2 goals shows example text messages)

315

316 [insert Fig. 2]

317

#### 318 Interventionist training, supervision and competency

319 The MTS role aims to provide patients with tailored behavioural and social support and information 320 to enable the continued change in smoking behaviours following discharge from a smoke-free mental 321 health ward. To fulfil the MTS role, prospective interventionists are required to have knowledge of 322 evidence-based methods in the treatment of tobacco dependency, including completion of the 323 National Centre for Smoking Cessation Training (NCSCT) Practitioner Training module and the 324 speciality course on smoking cessation and mental health. A bespoke training session designed to 325 address the practicalities of smoking behaviour change in people with mental illness, and which 326 covers e-cigarette use and interactions between tobacco smoke and certain antipsychotic 327 medications (e.g., clozapine) in line with Royal College of Psychiatrists guidance, [27, 28] will be 328 delivered.

329

330 MTSs will undertake self-guided online training supplemented with an in-person training session on 331 the delivery of the manualised SCEPTRE intervention facilitated by members of the core SCEPTRE 332 research team. Both clinical supervision, provided by the TRUST PI or nominated individual and 333 procedural supervision, provided by members of the core SCEPTRE research team, on a fortnightly 334 basis will be provided throughout the interventional period of the study. Fidelity of intervention 335 delivery will be optimised through monthly supervision sessions and monitored using self-336 assessment checklists and logs for MTSs delivering the intervention. The log will allow MTSs to 337 record all contacts with participants, and the research team will judge the degree to which the 338 intervention as designed has been delivered in practice. Additional random fidelity checks will be 339 carried out.

340

#### 341 Outcome measures and progression criteria

342 The schedule of data collection is shown in (Fig. 3) the SPIRIT Figure.

343

344 [insert Fig. 3]

345

346 **Primary feasibility outcomes** 

- The primary outcome of this feasibility trial will be to assess whether prespecified progression criteria are met to progress to the full randomised trial of the SCEPTRE intervention. Progression criteria are based on participant recruitment, retention, number of trusts enrolled and the feasibility of collecting carbon monoxide readings (Table 2).
- 351
- 352

## 353 Table 2. SCEPTRE feasibility study progression criteria

Progression criterion	Target at end of internal pilot	<b>Green</b> (Progression to full RCT without major modifications)	<b>Amber</b> (Progression to full RCT may be possible with modifications)	<b>Red</b> (Full RCT not feasible)
Participant recruitment	64 Participants recruited	100% (64)	60-99% (38-64)	<60% (<38)
Participant retention (Primary outcome data available at 6 months)	At least 80%	80-100% (51-64)	60-80% (38-51)	<60% (<38)
Trusts enrolled Each Trust expected to provide 1-2 sites/wards (can be more)	8	80-100% (6-8)	60-80% (5-6)	<60% (<5)
Feasibility of collecting carbon monoxide reading (biochemically validated primary outcome measure)	CO reading collected for at least 75% of all participants (intervention and control group) reporting to be abstinent	75-100% (absolute figures to be confirmed)	50-75%	<50

354

## 355 **Proposed trial outcome measures**

All participants will be asked to complete follow-up questionnaires with a member of the research

team at 3- and either 4-, 5-, or 6-months post-randomisation (see Fig. 3).

358

359 <u>Smoking-related measures:</u> Smoking status; 7-day point prevalence abstinence validated by exhaled

360 CO <10ppm, self-reported relapse following discharge from hospital, continuous abstinence, quit

361 attempts, nicotine dependence as assessed by the Heaviness of Smoking Index (HSI) [30], strength of

362 urges to smoke [31], level of motivation to quit as assessed by the Motivation to Stop Smoking

363 Questionnaire [32] to assess how motivation changes over time and affects cessation outcomes, self-

364 efficacy related to smoking cessation and use of e-cigarettes and NRT since discharge.

365

Mental and physical health measures: The nine-item Patient Health Questionnaire depression scale (PHQ-9) [33], the Generalised Anxiety Disorder 7-item scale (GAD-7) [34], and the quality-of-life scale (EQ-5D) [35], will be included. Frequency of use of health services (health economic data) since discharge will also be collected.

370

We will review the suitability and definitions of the two core smoking-related outcome measures, as per current debate in the field [36], as follows: for 7-day point prevalence abstinence, we will review and potentially adjust downward the CO threshold of <10 ppm for biochemical validation, depending on suitability of this approach for our patient population; for the multiple continuous abstinence outcome measures (1 – 6 months), we will review availability and congruency of data and define one consistent secondary outcome measure accordingly.

377

## 378 Sample size considerations

379 The feasibility study will be conducted across approximately 12 acute adult mental health inpatient 380 wards of the participating eight Trusts. Based on combined monthly discharge figures of ~200 381 patients, of which we estimate conservatively that ~140 will be eligible to participate, a smoking 382 prevalence of ~60%, and a conservative estimate of willingness of smokers to take part of 20%, we 383 will aim to recruit a minimum of 64 patients, who will be individually randomised, at a 1:1 ratio, to 384 the SCEPTRE intervention or the control arm. A trial of this size [37] will also allow a participation 385 rate of 15% and completion rate of 80% to be estimated within a 95% confidence interval of  $\pm$ 3% and 386 ±10% respectively [38].

387

#### 388 Additional qualitative and quantitative measures of feasibility and acceptability

In line with recommendations for the reporting of protocols of pilot and feasibility trials [29], a range
 of quantitative and qualitative data for all participants (intervention and control arm) determining
 the acceptability and feasibility of intervention delivery and research procedures will be collected.

392

## 393 <u>Recruitment and retention</u>

394 All participants screened will be recorded in the eligibility screening log, with reasons for ineligibility

and approach outcomes (outlined above). Retention rates will be monitored throughout the duration

of the study and the flow of participants will be detailed in a CONSORT diagram.

397

## 398 <u>Compliance with the protocol</u>

In addition to the interviews with MTSs (see above), compliance to the protocol and fidelity of intervention delivery will be optimised through monthly supervision sessions and monitored using self-assessment checklists and logs for MTSs delivering the intervention. The log will allow MTSs to record all contacts with participants, and the research team will judge the degree to which the intervention as designed has been delivered in practice. Any deviations from the protocol will be reported to YTU using a protocol deviation log.

405

## 406 Level of contamination and suitability of randomisaton approach

407 The suitability of the individual randomisation approach will be assessed by using qualitative and 408 quantitative data of control group participants who quit or reduced smoking at 3- and 4, 5, or 6-409 months post-randomisation. Quantitative investigation will take place in the context of follow-up, to 410 identify and specify smoking behaviour change. Qualitative data will be obtained via interviews 411 (outlined above) to investigate reasons for smoking behaviour change and identify potential 412 (unintentional) links with the SCEPTRE intervention. Based on our findings, we will estimate the 413 presence/extent of contamination in the control group, and the need to change the unit of 414 randomisation to clusters. If more than 30% of control participants appear to have changed aspects 415 of their smoking behaviour due to factors directly related to our intervention, we will consider 416 strategies to reduce contamination in the full RCT, including the possibility of designing the full RCT 417 as a cluster trial, with wards as the unit of randomisation.

418

## 419 Data management

Each site will hold data according to the General Data Protection Regulations (GDPR) and the Data
Protection Act 2018. All data will be stored on a secure password-protected server and archived for
10 years after study completion. Patients will be assigned a unique trial number and this will be used
on CRFs; patients will not be identified by their name in order to maintain confidentiality.

424

#### 425 Data analysis

426 A statistical analysis plan (SAP) giving details of the planned analyses will be drafted before data

427 collection has been completed and reviewed by the Programme Management Group (PMG) and PSC.

428 A brief description of the planned analyses is given below.

430 The statistical analysis will be carried out by a statistician based in YTU, using Stata v17 or later. The 431 reporting of this trial will follow CONSORT guidelines for pilot and feasibility trials [22]. A flow 432 diagram will be produced, depicting the flow of patients through the trial. The number of patients 433 screened, eligible, consenting, and randomised will be summarised, with reasons for ineligibility and 434 non-consent given where available. Baseline data will be summarised descriptively by randomised 435 group, with no formal statistical comparisons being undertaken [39]. Continuous variables will be 436 summarised using descriptive statistics, while categorical variables will be summarised using counts 437 and percentages. Descriptive statistics will summarise participant outcomes by randomised group 438 and timepoint, including the amount of missing data. Relevant measures of recruitment and 439 retention will be calculated and compared against the pilot progression criteria. The recruitment rate 440 will be estimated and presented alongside a corresponding 95% confidence interval. Measures of 441 contamination and participant engagement with the multiple components of the intervention will be 442 summarised descriptively.

443

444 Health economic analysis will be conducted as a preparatory step towards a comprehensive 445 economic evaluation in the subsequent definitive RCT. Costs associated with the delivery of the 446 SCEPTRE intervention and usual care will be estimated. All resources used in the provision of the 447 intervention, such as the training for the MTSs, the staff time spent on delivering the intervention, 448 and the NRT and e-cigarettes dispensed, will be recorded alongside the trial. Data on the resources 449 used in usual care through self-completed questionnaires at 3- and either 4-, 5-, or 6-months post-450 randomisation will be collected. A micro-costing approach, collecting detailed information about 451 health service use, will be applied to generate estimated intervention costs for both arms by 452 multiplying the quantity of each identified resource by its corresponding unit cost. We will pilot the 453 data collection tools used to gather health economics data. We will test the feasibility and 454 acceptability of the health service use questionnaire and the outcome measure instrument (i.e., the 455 EQ-5D-5L questionnaire). We will examine the completion rates, identify any challenges or barriers to 456 completion, and make necessary modifications to the questionnaires for use in the full trial. The 457 methods and findings will be summarised in a report that can be used to inform the design and 458 conduct of the economic evaluation in the full trial stage.

459

460 Qualitative data analysis will be undertaken by group, e.g., participants, MTSs, friends/family, Trust 461 stakeholders. Data will be analysed using NVivo software (QSR International Pty Ltd, Melbourne, 462 Australia). First, an inductive approach using thematic analysis will be used to identify nodes and 463 sub-themes in the data [40]. Transcripts will be coded line by line by two researchers, with

preliminary code names assigned to the data items and iteratively developed. Preliminary codes will be checked and discussed with a third researcher, experienced in qualitative research and the behaviour change wheel. Following this, a deductive approach will be used to chart sub-themes to the APEASE (Acceptability, Practicability, Effectiveness, Affordability, Side-effects, and Equity) criteria. The data will be presented and discussed in a wider research team meeting to refine and confirm the final interpretation.

470

#### 471 Trial management

472 A Programme Management Group (PMG) has been established to oversee the day-to-day 473 management (e.g., protocol and ethics approvals, set-up, recruitment, data collection, data 474 management) of the study, and is chaired by the Chief Investigator (CI). Membership includes co-Cls, 475 co-investigators, research staff on the project and PPI representation. The role of the PMG is to 476 monitor all aspects of the conduct and progress of the trial, ensure that the protocol is adhered to 477 and take appropriate action to safeguard participants and the quality of the trial itself. Throughout 478 the project there will be regular videoconference contact supplemented by face-to-face meetings 479 where required. Frequency of meetings will vary depending on the stage of the trial. The PMG, 480 through the York Trials Unit (YTU), will provide feedback on trial progress to the Programme Steering 481 Committee (PSC) established to provide overall independent oversight for SCEPTRE on behalf of the 482 Sponsor and Project Funder and to ensure that the project is conducted to the rigorous standards set 483 out in the Department of Health's Research Governance Framework for Health and Social Care and 484 the Guidelines for Good Clinical Practice (GCP). Furthermore, the PMG through the YTU, will provide 485 feedback to the Data Monitoring and Ethics Committee (DMEC) established to monitor safety and 486 efficacy data as well as quality and compliance data and ensure that the protocol is accurately 487 followed, and the study is GCP compliant.

488

#### 489 Ethics

The protocol (Version 1.0\_05.09.2023) for this study and the informed consent form (see online supplemental appendix 2) were approved by the North West - Greater Manchester West Research Ethics Committee (REC) (23/NW/0312). The Investigators will ensure that this study is conducted in full conformity with current regulations, the current revision of the Declaration of Helsinki, and with the principles of GCP. We will adhere to the UK Framework for Health and Social Care Research [22, 39]. The programme manager/CI will obtain approval for all amendments.

496

#### 497 Adverse events

498 All adverse events (AEs) occurring during the study observed by the investigator or reported by MTSs 499 or participants, will be recorded on the SCEPTRE Adverse Event Form for return to YTU. All serious 500 adverse events (SAEs) will be entered onto the SAE reporting form and sent via REDCap or encrypted 501 email to YTU within 24 hours of the investigator becoming aware of the event. Once received, 502 causality and expectedness will be confirmed by the CI or a medical co-applicant or PSC member not 503 acting as a site Principal Investigator (PI). Any change of condition or other follow-up information 504 should be sent as soon as it is available or at least within 24 hours of the information becoming 505 available. Events will be followed up until the event has resolved or a final outcome has been 506 reached. SAEs that are deemed to be unexpected and related to the trial will be notified to the REC 507 and sponsor within 15 days by YTU. All such events will be reported to the PSC and DMEC at their 508 next meetings. Protocols and SOPs have been developed to identify and manage risks of suicide and 509 harm to participants.

510

#### 511 Dissemination

512 We will share results widely through local, national and international academic, clinical and PPI 513 networks. The results will be disseminated through conference presentations, peer reviewed journals 514 and will be published on the trial website: <u>https://sceptreresearch.com/</u>.

515

#### 516 Trial status

517 This protocol (V.1.0) was approved on 6<sup>th</sup> November 2023. Recruitment to the SCEPTRE feasibility 518 study opened on 23 January 2024 with the first participant randomised on 13<sup>th</sup> February 2024. The 519 trial is ongoing. Reporting of the trial is anticipated in the first quarter of 2025.

520

#### 521 DISCUSSION

522 In line with NICE recommendations, that mental health settings become entirely smokefree, and that 523 mental health patients should have access to evidence-based stop smoking treatment [14], SCEPTRE 524 aims to test ways to support mental health inpatients after discharge in maintaining or achieving 525 abstinence from tobacco smoking. At present, no evidence-based strategies to help maintain or achieve a smokefree lifestyle and avoid relapse after discharge exist. As such, SCEPTRE feasibility 526 527 study will inform the design of a future large-scale randomised controlled trial. This large-scale trial 528 will aim to test the effectiveness and cost-effectiveness of a complex intervention to promote or 529 maintain smoking-related behaviour change among patients following discharge from a smoke-free 530 mental health inpatient setting. One limitation of this study is the potential for contamination in the 531 control group. However, we will assess and estimate the presence/extent of this, and the need to

change the unit of randomisation to clusters. Secondly, this is a multi-component intervention which makes it difficult to delineate impact very clearly. The process evaluation will aim to provide insights on the importance of individual intervention components. The study is focused on acute adult mental health departments making generalisation beyond this setting difficult. Usual care is heterogeneous and policy/practice landscapes are shifting rapidly. We will collect information on what usual care entails on each inpatient ward.

538

539 If effective and implemented in NHS mental health settings, the SCEPTRE intervention will directly 540 benefit patients (and their families) and has the potential to save lives and NHS resources, and to 541 decrease health inequalities that exists for people with mental health conditions.

542

#### 543 Acknowledgements

We wish to thank the SCEPTRE PPI Panel for their assistance in the development of patient/participant processes and materials. We also acknowledge the valuable contributions of the NCSCT for their assistance in the development and delivery of MTS training on smoking and mental health, and the Smoke Free App team for their contributions to the development of processes and materials to support participant engagement with the Smoke Free App.

549

#### 550 Authors' Contributions

551 ER conceived the idea for the study. ER, LH, ES, LC, ML, and CP led the development of the 552 intervention. VE is the Trial Co-ordinator and SB and LSinclair are the trial managers. AM and FW are 553 the study statisticians. GR, SG, CH, TC, JW, SP, PC, MH, JB, ML, CP, PG, LShahab, LC and MH are co-554 applicants and SH is the independent PPI co-applicant. JB, PC, TC, PG, SG, CH, SP, LShahab, and JW 555 provide academic expertise. PPW drafted the manuscript. All authors contributed to protocol writing 556 and approved the final version.

557

#### 558 Funding statement

The SCEPTRE Feasibility Trial is funded by Programme Grants for Applied Research (NIHR200607). The sponsor is the Sheffield Health and Social Care NHS Foundation Trust. Catherine Hewitt, Simon Gilbody and Tim Coleman are NIHR Senior Investigators. The trial will be monitored and audited in accordance with the sponsor's procedures. The sponsor will play no role in the study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication. PPW, LH, ES, and ER are supported by the NIHR Yorkshire and Humber Applied Research Collaboration.

E	۲	۲
	53	53

## 567 **Competing interest statement**

568	LS has received honoraria for talks, an unrestricted research grant and travel expenses to attend
569	meetings and workshops from Pfizer and an honorarium to sit on advisory panel from Johnson $\&$
570	Johnson, both pharmaceutical companies that make smoking cessation products. He has acted as
571	paid reviewer for grant awarding bodies and as a paid consultant for health care companies. Other
572	research has been funded by the Department of Health, UKRI, a community-interested company
573	(National Centre for Smoking Cessation) and charitable sources (Cancer Research UK, Yorkshire
574	Cancer Research). He has never received personal fees or research funding of any kind from alcohol,
575	electronic cigarette or tobacco companies. All other authors declare no conflicts of interest.
576	
577	
578	
579	
580	
581	
582	
583	
584	
585	
586	
587	
588	
589	
590	
591	
592	
593	
594	
595	
596	
597	
598	
599	

600		
601		
<u> </u>		
602		
603		
604		
COE		
605		
606		
607	REFER	ENCES
608 609 610 611	1.	Digital, N. <i>Statistics on Smoking, England 2020.</i> 2020 [cited 2023 08/08]; Available from: <u>https://digital.nhs.uk/data-and-information/publications/statistical/statistics-on-</u> <u>smoking/statistics-on-smoking-england-2020/part-1-smoking-related-ill-health-and-</u> <u>mortality</u> .
612	2.	Digital, N., Statistics on Smoking, England - 2016 2016.
613 614	3.	Richardson, S., A. McNeill, and L.S. Brose, <i>Smoking and quitting behaviours by mental health conditions in Great Britain (1993–2014)</i> . Addictive behaviors, 2019. <b>90</b> : p. 14-19.
615	4.	Psychiatrists, R.C.o.P.R.C.o., Smoking and mental health. 2013: London.
616	5.	Meltzer, H., et al., The prevalence of psychiatric morbidity among adults living in institutions.
617		International Review of Psychiatry, 2003. 15(1-2): p. 129-133.
618	6.	Cheeseman H, H.H., The stolen years: The mental health and smoking action report 2016:
619		London.
620	7.	Peckham, E., et al., Smoking cessation in severe mental ill health: what works? An updated
621	•	systematic review and meta-analysis. BMC psychiatry, 2017. <b>17</b> (1): p. 1-18.
622	8.	Brose, L.S., et al., Mental health, smoking, harm reduction and quit attempts – a population
623 624	Q	Survey in England. BMC Public Health, 2020. <b>20</b> (1): p. 1237.
625	5.	health conditions' a survey of NHS ston smoking services BMC Health Services Research
626		2010. <b>10</b> : p. 1-5.
627	10.	McNally, L., C. Todd, and E. Ratschen, <i>The prevalence of mental health problems among users</i>
628		of NHS stop smoking services: effects of implementing a routine screening procedure. BMC
629		health services research, 2011. <b>11</b> (1): p. 1-4.
630	11.	Knowles, S., et al., Making the journey with me: a qualitative study of experiences of a
631		bespoke mental health smoking cessation intervention for service users with serious mental
632		<i>illness.</i> BMC psychiatry, 2016. <b>16</b> : p. 1-9.
633	12.	Peckham, E., et al., Smoking Cessation Intervention for severe Mental III Health Trial
634		(SCIMITAR): a pilot randomised control trial of the clinical effectiveness and cost-effectiveness
635		of a bespoke smoking cessation service. Health Technology Assessment (Winchester,
636	4.2	England), 2015. <b>19</b> (25): p. 1-148, v.
637	13.	Parker, C., A. McNeill, and E. Ratschen, <i>Tailored tobacco dependence support for mental</i>
638		nealth patients: a model for inpatient and community services. Addiction, 2012. 107: p. 18-
639	14	25. NICE Tobacco: proventing untake, promoting quitting and treating dependence [NG200]
640 641	14.	2021: Available from: https://www.pice.org.uk/guidance/pg209
642	15	Brose, I.S., F. Simonavicius, and A. McNeill, Maintaining abstinence from smoking after a
643		period of enforced abstinence-systematic review, meta-analysis and analysis of behaviour
644		change techniques with a focus on mental health. Psychological medicine, 2018. <b>48</b> (4): p.
645		669-678.

- 64616.Shoesmith, E., et al., Supporting smoking cessation and preventing relapse following a stay in647a smoke-free setting: a meta-analysis and investigation of effective behaviour change648techniques. Addiction, 2021. 116(11): p. 2978-2994.
- Prochaska, J.J., et al., *Return to smoking following a smoke-free psychiatric hospitalization.*American Journal on Addictions, 2006. **15**(1): p. 15-22.
- Mussulman, L.M., et al., *Rapid relapse to smoking following hospital discharge*. Preventive
  medicine reports, 2019. 15: p. 100891.
- Chan, A.W., et al., SPIRIT 2013 statement: defining standard protocol items for clinical trials.
  Ann Intern Med, 2013. 158(3): p. 200-7.
- Alvarez, G., F. Cerritelli, and G. Urrutia, Using the template for intervention description and
  replication (TIDieR) as a tool for improving the design and reporting of manual therapy
  interventions. Man Ther, 2016. 24: p. 85-9.
- Shoesmith, E., et al., Promoting and Maintaining Changes in Smoking Behavior for Patients
  Following Discharge from a Smoke-free Mental Health Inpatient Stay: Development of a
  Complex Intervention Using the Behavior Change Wheel. Nicotine and Tobacco Research,
  2023. 25(4): p. 729-737.
- Eldridge, S.M., et al., CONSORT 2010 statement: extension to randomised pilot and feasibility
  trials. bmj, 2016. 355.
- 66423.Michie, S., L. Atkins, and R. West, The behaviour change wheel. A guide to designing665interventions. 1st ed. Great Britain: Silverback Publishing, 2014. 1003: p. 1010.
- Cane, J., D. O'Connor, and S. Michie, Validation of the theoretical domains framework for use *in behaviour change and implementation research*. Implementation science, 2012. 7: p. 1-17.
- Michie, S., et al., *The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions*. Annals of behavioral medicine, 2013. 46(1): p. 81-95.
- Huddlestone, L., et al., A systematic review of mental health professionals, patients, and
  carers' perceived barriers and enablers to supporting smoking cessation in mental health
  settings. Nicotine and Tobacco Research, 2022. 24(7): p. 945-954.
- 674 27. Physicians, R.C.o. and R.C.o. Psychiatrists. Smoking and mental health 2013 [cited 2022 23
  675 November]; Available from: <u>https://www.rcplondon.ac.uk/projects/outputs/smoking-</u>
  676 andmental-health
- 677 28. Royal College of Psychiatrists, The prescribing of varencline and vaping (eletronic cigarettes)
  678 to patients with severe mental illness. Position Statement (PS05/18). 2018.
- Thabane, L. and G. Lancaster, A guide to the reporting of protocols of pilot and feasibility
  trials. Pilot and Feasibility Studies, 2019. 5(1): p. 37.
- Borland, R., et al., *The reliability and predictive validity of the Heaviness of Smoking Index and its two components: findings from the International Tobacco Control Four Country study.*Nicotine & Tobacco Research, 2010. **12**(suppl\_1): p. S45-S50.
- Fidler, J.A., L. Shahab, and R. West, Strength of urges to smoke as a measure of severity of *cigarette dependence: comparison with the Fagerström Test for Nicotine Dependence and its components.* Addiction, 2011. **106**(3): p. 631-638.
- 68732.(NCSCT),N.C.f.S.C.a.T.MotivationtoStopSmokingAvailablefrom:688<a href="https://www.ncsct.co.uk/usr/pub/Motivation%20to%20stop%20smoking.pdf">https://www.ncsct.co.uk/usr/pub/Motivation%20to%20stop%20smoking.pdf</a>.
- Kroenke, K., R.L. Spitzer, and J.B. Williams, *The PHQ-9: validity of a brief depression severity measure.* Journal of general internal medicine, 2001. 16(9): p. 606-613.
- 691 34. Spitzer, R.L., et al., A brief measure for assessing generalized anxiety disorder: the GAD-7.
  692 Archives of internal medicine, 2006. 166(10): p. 1092-1097.
- Byford, S., The validity and responsiveness of the EQ-5D measure of health-related quality of
  life in an adolescent population with persistent major depression. Journal of mental health,
  2013. 22(2): p. 101-110.

- 696 36. Benowitz, N.L., et al., *Biochemical Verification of Tobacco Use and Abstinence: 2019 Update.*697 Nicotine Tob Res, 2020. 22(7): p. 1086-1097.
- 69837.Metse, A.P., et al., Efficacy of a universal smoking cessation intervention initiated in inpatient699psychiatry and continued post-discharge: A randomised controlled trial. Australian & New700Zealand Journal of Psychiatry, 2017. 51(4): p. 366-381.
- 70138.Hertzog, M.A., Considerations in determining sample size for pilot studies. Research in702nursing & health, 2008. **31**(2): p. 180-191.
- 39. Senn, S., *Testing for baseline balance in clinical trials*. Statistics in medicine, 1994. 13(17): p.
  1715-1726.
- 705 40. Braun, V. and V. Clarke, *Thematic analysis*. 2012: American Psychological Association.